No Data
No Data
Bai Li Tian Heng (688506.SH): 2 indications of BL-B01D1 for EGFR sensitive mutations and EGFR wild-type non-small cell lung cancer patients are included in the list of breakthrough therapies for injection.
Glory 7th, 10th|Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical BL-B01D1 independently developed by the company is used for locally advanced or metastatic non-squamous non-small cell lung cancer patients with EGFR-sensitive mutations who have failed EGFR-TKI treatment, and is also used for the treatment of locally advanced or metastatic EGFR wild-type non-small cell lung cancer patients who have failed previous anti-PD-1/PD-L1 monoclonal antibody treatment and platinum-containing chemotherapy. Two indications have been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration Drug Evaluation Center (referred to as the "Drug Evaluation Center").
US FDA Allows Trial of Sichuan Biokin Pharma-Bristol-Myers Squibb's Cancer Drug
Bailitianheng (688506.SH): The BL-B01D1 combination therapy project for advanced solid tumors has obtained FDA approval for phase 1/2a clinical trial application.
On September 29, Geelong Hui announced that its partner, Bristol-Myers Squibb (BMS), with the New York Stock Exchange code: BMY, has received a notification from the Food and Drug Administration (FDA) of the United States that the BL-B01D1 combination therapy project for the treatment of advanced solid tumors has obtained FDA approval for a phase 1/2a clinical trial application.
Sichuan Biokin Pharmaceutical Gets Clinical Trial Approval for Tumor Antibody Injection
Baili Tianheng (688506.SH): GNC-077 specific antibody injection project for the treatment of advanced solid tumors has obtained the approval letter for Phase I clinical trial.
On September 22, Boletimes (688506.SH) announced that the company has recently received the officially approved notification letter for the approval of the clinical trial of the pharmaceutical issued by the National Medical Products Administration (NMPA). The company's independently developed innovative biopharmaceutical, GNC-077, has obtained approval for the clinical trial.
Summary of the Semi-annual Report of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. in 2024
No Data
No Data